Albany Molecular Research, Inc. (NASDAQ:AMRI) Position Increased by Parametric Portfolio Associates LLC

Parametric Portfolio Associates LLC increased its position in shares of Albany Molecular Research, Inc. (NASDAQ:AMRI) by 24.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 36,527 shares of the biotechnology company’s stock after purchasing an additional 7,187 shares during the period. Parametric Portfolio Associates LLC owned 0.09% of Albany Molecular Research worth $793,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Arizona State Retirement System boosted its stake in shares of Albany Molecular Research by 0.9% during the 2nd quarter. Arizona State Retirement System now owns 11,686 shares of the biotechnology company’s stock worth $254,000 after purchasing an additional 100 shares during the period. Texas Permanent School Fund raised its holdings in shares of Albany Molecular Research by 0.9% in the 2nd quarter. Texas Permanent School Fund now owns 16,299 shares of the biotechnology company’s stock valued at $354,000 after purchasing an additional 151 shares in the last quarter. Municipal Employees Retirement System of Michigan raised its holdings in shares of Albany Molecular Research by 5.8% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 5,260 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 290 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of Albany Molecular Research by 0.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 101,876 shares of the biotechnology company’s stock worth $2,211,000 after acquiring an additional 589 shares in the last quarter. Finally, Thrivent Financial For Lutherans raised its stake in shares of Albany Molecular Research by 5.4% during the 1st quarter. Thrivent Financial For Lutherans now owns 12,640 shares of the biotechnology company’s stock worth $177,000 after acquiring an additional 650 shares in the last quarter. Hedge funds and other institutional investors own 72.10% of the company’s stock.

Separately, BidaskClub upgraded shares of Albany Molecular Research from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. Five research analysts have rated the stock with a hold rating, The stock currently has a consensus rating of “Hold” and a consensus price target of $18.00.

Albany Molecular Research, Inc. (NASDAQ:AMRI) remained flat at $$21.74 during trading hours on Wednesday. The company had a trading volume of 531,200 shares, compared to its average volume of 872,120. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.37 and a current ratio of 0.68. Albany Molecular Research, Inc. has a one year low of $13.01 and a one year high of $22.17.

COPYRIGHT VIOLATION WARNING: This story was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://stocknewstimes.com/2017/12/06/parametric-portfolio-associates-llc-acquires-7187-shares-of-albany-molecular-research-inc-amri.html.

Albany Molecular Research Profile

Albany Molecular Research, Inc is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing.

Institutional Ownership by Quarter for Albany Molecular Research (NASDAQ:AMRI)

Receive News & Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply